Cybrexa Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$40.2M
- Investors
-
7
Cybrexa Therapeutics General Information
Description
Developer of oncology therapeutics designed for antigen-independent intracellular drug delivery. The company's therapeutics rapidly bring novel compounds with robust IP to pivotal studies, enable potent drugs and combination therapies that are currently limited by toxicity, and expand the efficacy of existing anticancer agents to larger, unmet-need populations, enabling physicians to improve patient outcomes and save lives by developing the next generation of cancer therapeutics.
Contact Information
Website
www.cybrexa.comCorporate Office
- 5 Science Park
- 395 Winchester Avenue
- New Haven, CT 06511
- United States
Corporate Office
- 5 Science Park
- 395 Winchester Avenue
- New Haven, CT 06511
- United States
Cybrexa Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 24-Jun-2022 | $40.2M | Completed | Clinical Trials - Phase 2 | ||
| 6. Debt - PPP | 27-Apr-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Grant | 01-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC (Series B1) | 20-Jun-2019 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 01-Jan-2019 | Completed | Clinical Trials - Phase 2 | |||
| 2. Early Stage VC (Series B) | 27-May-2017 | $6.08M | $6.78M | Completed | Clinical Trials - Phase 2 | |
| 1. Early Stage VC (Series A) | $700K | $700K | Completed | Startup |
Cybrexa Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Cybrexa Therapeutics Comparisons
Industry
Financing
Details
Cybrexa Therapeutics Competitors (38)
One of Cybrexa Therapeutics’s 38 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| Kymera Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Centrose | Venture Capital-Backed | Madison, WI | ||||
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA |
Cybrexa Therapeutics Patents
Cybrexa Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019136298-A1 | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | Inactive | 05-Jan-2018 |
Cybrexa Therapeutics Signals
Cybrexa Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advantage Capital (Louisiana) | PE/Buyout | Minority | ||
| Elm Street Ventures | VC-Backed Company | Minority | ||
| Singh Capital Partners | Family Office | Minority | ||
| Cycle Venture Partners | Venture Capital | Minority | ||
| National Cancer Institute | Government |
Cybrexa Therapeutics FAQs
-
When was Cybrexa Therapeutics founded?
Cybrexa Therapeutics was founded in 2017.
-
Where is Cybrexa Therapeutics headquartered?
Cybrexa Therapeutics is headquartered in New Haven, CT.
-
What is the size of Cybrexa Therapeutics?
Cybrexa Therapeutics has 11 total employees.
-
What industry is Cybrexa Therapeutics in?
Cybrexa Therapeutics’s primary industry is Drug Delivery.
-
Is Cybrexa Therapeutics a private or public company?
Cybrexa Therapeutics is a Private company.
-
What is Cybrexa Therapeutics’s current revenue?
The current revenue for Cybrexa Therapeutics is .
-
How much funding has Cybrexa Therapeutics raised over time?
Cybrexa Therapeutics has raised $47M.
-
Who are Cybrexa Therapeutics’s investors?
Advantage Capital (Louisiana), Elm Street Ventures, Singh Capital Partners, Cycle Venture Partners, and National Cancer Institute are 5 of 7 investors who have invested in Cybrexa Therapeutics.
-
Who are Cybrexa Therapeutics’s competitors?
Regenxbio, Genetix Biotherapeutics, Kymera Therapeutics, Centrose, and Marengo Therapeutics are some of the 38 competitors of Cybrexa Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process